NEW YORK (GenomeWeb) – Sygnis said today that it has signed a distribution agreement with Cambridge Bioscience for the commercialization of Sygnis' product portfolio in the UK and Ireland.

Under the agreement, Cambridge Bioscience will promote, market, sell, and support Sygnis' TruePrime products for primer-free whole-genome amplification, as well as its SunScript thermostable reverse transcriptase kits to molecular biologists.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.